Primary Risk Drivers
Below is a snapshot of domains that materially influence the MARA Rating.
Clinical effectiveness
Ozanimod shows moderate benefit over placebo in achieving clinical remission for both TNF-alpha inhibitor-naive and TNF-alpha inhibitor-experienced subgroups, as evidenced by the phase 3 TRUENORTH trial. However, there is no direct evidence comparing ozanimod with standard treatments, leading to a moderate rating.
Cost effectiveness
Ozanimod is considered cost-effective compared to most treatments, with ICERs within acceptable ranges, except when compared to infliximab in the TNF-alpha inhibitor-naive subgroup. This suggests a defensible cost-effectiveness profile.
Quality of life
The committee noted that ulcerative colitis significantly impacts quality of life, and ozanimod’s ability to induce remission is likely to improve HRQoL. However, specific HRQoL data from validated instruments were not detailed in the document, leading to a moderate rating.
Supporting Domains
Safety and Adverse Effects
Ozanimod has a good safety profile with manageable adverse effects, primarily mild to moderate. The committee acknowledged the importance of safety in treatment decisions, supporting a strong rating.
Comparator Selection
The document indicates that while ozanimod was compared to relevant treatments, the lack of direct head-to-head trials necessitated reliance on indirect comparisons, which introduces some uncertainty.
Patient Population and Subgroups
The trial population in TRUENORTH is representative of the intended patient population in Healthcare practice, with appropriate subgroup analyses based on TNF-alpha inhibitor experience, supporting a strong rating.
Care Pathway Integration
Ozanimod can be integrated into existing treatment pathways with minor adjustments, as it provides a new oral option for patients who have not responded to conventional therapies.
Resource Use and Cost Implications
The budget impact of ozanimod is manageable, and the commercial arrangement provides a discount, indicating a favorable resource use profile.
Evidence Quality and Robustness
The evidence base is supported by a phase 3 RCT and network meta-analyses, although some limitations in estimating baseline placebo risk were noted. Overall, the evidence is robust.
Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the efficacy estimates due to the reliance on indirect comparisons, the context of unmet need and the potential benefits of ozanimod mitigate some concerns.
